EP3856195A4 - Methods and compositions for treating aging-associated impairments using ccr3-inhibitors - Google Patents
Methods and compositions for treating aging-associated impairments using ccr3-inhibitors Download PDFInfo
- Publication number
- EP3856195A4 EP3856195A4 EP19867321.2A EP19867321A EP3856195A4 EP 3856195 A4 EP3856195 A4 EP 3856195A4 EP 19867321 A EP19867321 A EP 19867321A EP 3856195 A4 EP3856195 A4 EP 3856195A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- ccr3
- inhibitors
- compositions
- methods
- treating aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000032683 aging Effects 0.000 title 1
- 230000006735 deficit Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737017P | 2018-09-26 | 2018-09-26 | |
| PCT/US2019/052995 WO2020069008A1 (en) | 2018-09-26 | 2019-09-25 | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3856195A1 EP3856195A1 (en) | 2021-08-04 |
| EP3856195A4 true EP3856195A4 (en) | 2022-06-22 |
Family
ID=69953286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19867321.2A Pending EP3856195A4 (en) | 2018-09-26 | 2019-09-25 | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3856195A4 (en) |
| JP (1) | JP2022502441A (en) |
| KR (1) | KR20210065950A (en) |
| CN (1) | CN112789044A (en) |
| AU (1) | AU2019346456A1 (en) |
| BR (1) | BR112021004938A2 (en) |
| CA (1) | CA3111433A1 (en) |
| CL (1) | CL2021000724A1 (en) |
| CO (1) | CO2021003713A2 (en) |
| EA (1) | EA202190463A1 (en) |
| IL (1) | IL281578A (en) |
| MA (1) | MA53743A (en) |
| MX (1) | MX2021002967A (en) |
| SG (1) | SG11202102105VA (en) |
| TW (1) | TW202027752A (en) |
| WO (1) | WO2020069008A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005090330A1 (en) * | 2004-03-22 | 2005-09-29 | Astrazeneca Ab | N-piperidine derivates as ccr3 modulators |
| US20130266646A1 (en) * | 2012-04-04 | 2013-10-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising ccr3 antagonists |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| WO2018187473A1 (en) * | 2017-04-05 | 2018-10-11 | Alkahest Inc. | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
| WO2018187503A1 (en) * | 2017-04-05 | 2018-10-11 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1996551A2 (en) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| DK2749554T3 (en) * | 2009-04-22 | 2018-04-03 | Sma Therapeutics Inc | 2,5-disubstituted arylsulfonamide CCR3 antagonists |
| UA109290C2 (en) * | 2010-10-07 | 2015-08-10 | Common Crystals and Salts of CCR3 Inhibitors | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
-
2019
- 2019-09-25 MA MA053743A patent/MA53743A/en unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/en active Pending
- 2019-09-25 CA CA3111433A patent/CA3111433A1/en active Pending
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/en unknown
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/en not_active Application Discontinuation
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/en active Application Filing
- 2019-09-25 JP JP2021517342A patent/JP2022502441A/en active Pending
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/en unknown
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/en active Pending
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 EA EA202190463A patent/EA202190463A1/en unknown
- 2019-09-26 TW TW108134938A patent/TW202027752A/en unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/en unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005090330A1 (en) * | 2004-03-22 | 2005-09-29 | Astrazeneca Ab | N-piperidine derivates as ccr3 modulators |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US20130266646A1 (en) * | 2012-04-04 | 2013-10-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising ccr3 antagonists |
| WO2018187473A1 (en) * | 2017-04-05 | 2018-10-11 | Alkahest Inc. | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
| WO2018187503A1 (en) * | 2017-04-05 | 2018-10-11 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2020069008A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MA53743A (en) | 2022-01-05 |
| CO2021003713A2 (en) | 2021-04-08 |
| IL281578A (en) | 2021-05-31 |
| AU2019346456A1 (en) | 2021-04-15 |
| TW202027752A (en) | 2020-08-01 |
| CA3111433A1 (en) | 2020-04-02 |
| EP3856195A1 (en) | 2021-08-04 |
| JP2022502441A (en) | 2022-01-11 |
| WO2020069008A1 (en) | 2020-04-02 |
| MX2021002967A (en) | 2021-08-11 |
| CN112789044A (en) | 2021-05-11 |
| CL2021000724A1 (en) | 2021-10-15 |
| BR112021004938A2 (en) | 2021-06-01 |
| SG11202102105VA (en) | 2021-04-29 |
| EA202190463A1 (en) | 2021-06-29 |
| KR20210065950A (en) | 2021-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3606525A4 (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors | |
| EP3823673A4 (en) | Anti-cd112r compositions and methods | |
| EP3297702A4 (en) | Methods and compositions for treating aging-associated impairments | |
| EP3924490A4 (en) | Methods for treating cholestasis | |
| EP3852608A4 (en) | Compositions and methods for glaucoma | |
| EP3735325A4 (en) | Surface treatment compositions and methods | |
| EP3307296A4 (en) | Methods and compositions for treating aging-associated conditions | |
| IL290840A (en) | Compositions and methods for cd123 modification | |
| EP3687524A4 (en) | Compositions and methods for treating ophthalmic conditions | |
| EP3931336A4 (en) | Compositions and methods for treating laminopathies | |
| EP3844500A4 (en) | Rp182 compositions and methods | |
| EP3801478A4 (en) | Methods and compositions for preventing or treating calciphylaxis | |
| EP3790557A4 (en) | Compositions and methods for improving strand biased | |
| EP3618850A4 (en) | Compositions and methods for treating ocular pathologies | |
| EP3801534A4 (en) | Compositions and methods for increasing tetrahydrobiopterin plasma exposure | |
| EP3752161A4 (en) | Methods for treating fibrosis | |
| EP3801620A4 (en) | Compositions and methods for treating pancreatitis | |
| ZA202007183B (en) | Compositions and methods for treating the eye | |
| EP3990394A4 (en) | Compositions and methods for treating wastewater | |
| EP3870210A4 (en) | Compositions and methods for treating or preventing fibrosis | |
| EP3755328A4 (en) | Compositions and methods for treating pruritus | |
| EP3921286A4 (en) | Methods and compositions for treating produced water | |
| EP3856195A4 (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors | |
| EP3856184A4 (en) | Compositions and methods for inhibiting acss2 | |
| EP3519050A4 (en) | Compositions and methods for treating ophthalmic conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20210325 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| RAV | Requested validation state of the european patent: fee paid |
Extension state: MD Effective date: 20210325 Extension state: MA Effective date: 20210325 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031535000 Ipc: A61K0031454500 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20220520 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20220516BHEP Ipc: A61P 25/16 20060101ALI20220516BHEP Ipc: A61P 25/00 20060101ALI20220516BHEP Ipc: A61K 9/00 20060101ALI20220516BHEP Ipc: A61K 47/00 20060101ALI20220516BHEP Ipc: A61K 33/00 20060101ALI20220516BHEP Ipc: A61K 31/00 20060101ALI20220516BHEP Ipc: A61P 1/00 20060101ALI20220516BHEP Ipc: A61K 31/4545 20060101AFI20220516BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20231201 |